RARE up +1.94% percent right now. $RARE High is at 42.60 and the Low 40.62 with current volume of 103,838.
Recent News posted below.
RARE Ultragenyx Pharmaceutical Inc. Recent Headline News
Ultragenyx Pharmaceutical misses by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST
RARE: 42.35 (+1.19)
Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Nov 10, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the third quarter ended September 30, 2014.
RARE: 42.35 (+1.19)
Ultragenyx to Present at the Credit Suisse Annual Healthcare Conference
GlobeNewswire - Tue Nov 04, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Credit Suisse Annual Healthcare Conference on November 11, 2014 at 7:30am MT at the Biltmore Hotel in Phoenix.
RARE: 42.35 (+1.19)
Ultragenyx Granted EU Orphan Drug Designation for KRN23 for the Treatment of X-Linked Hypophosphatemia
GlobeNewswire - Thu Oct 30, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the European Commission has granted orphan medicinal product designation for recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23 (KRN23 or UX023) for the treatment of X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
RARE: 42.35 (+1.19)
Ultragenyx's Glut1 DS product candidate tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:51AM CDT
RARE: 42.35 (+1.19)
Ultragenyx Granted Orphan Drug Designation for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome
GlobeNewswire - Mon Oct 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS). Glut1 DS, also known as De Vivo disease, is a rare and potentially severely debilitating disease characterized by seizures, developmental delay, and movement disorder. Ultragenyx is conducting a Phase 2 study of triheptanoin in patients with Glut1 DS.
RARE: 42.35 (+1.19)
Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.01 (-0.31), EBS: 24.51 (+0.56), RARE: 42.35 (+1.19), LGND: 56.95 (+1.27)
Ultragenyx Pharmaceutical is Now Oversold (RARE)
MarketNewsVideo.com - Tue Oct 14, 3:34PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
RARE: 42.35 (+1.19)
Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
GlobeNewswire - Mon Oct 13, 8:45AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a Phase 2 extension study of sialic acid extended-release (SA-ER, UX001) tablets in patients with hereditary inclusion body myopathy (HIBM; also known as GNE myopathy), a rare, progressive muscle-wasting disease. SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM. The data were presented at the 19 International Congress of the World Muscle Society (WMS) in Berlin.
RARE: 42.35 (+1.19)
Ultragenyx to Present at the Leerink Partners Rare Disease Roundtable
GlobeNewswire - Wed Sep 24, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Leerink Partners Rare Disease Roundtable on October 1, 2014 at 9:40am ET at the Le Parker Meridien Hotel in New York.
RARE: 42.35 (+1.19)
Move Over Alibaba, These Are The Top 5 IPOs Of 2014
at Investor's Business Daily - Tue Sep 23, 7:02AM CDT
The Alibaba Group (BABA) mania may be cooling down but the IPO market continues to roar. The 2014 market for initial public offerings has been the busiest period since the 1999-2000 era of the dot-com bubble mania. There have been 195 IPOs on U.S....
GPRO: 74.45 (-1.30), RARE: 42.35 (+1.19), RWLK: 29.52 (-0.63), LOCO: 35.28 (-1.31), ZEN: 23.16 (-1.07), BABA: 114.72 (-4.43)
IPO Stock Watch: ReWalk Joins An Exclusive IPO Club
at Investor's Business Daily - Mon Sep 15, 5:56PM CDT
ReWalk Robotics (RWLK) stock rose 45% Monday on the heels of its eye-popping IPO Friday that joined an exclusive group. ReWalk was the fifth initial public offering this year to fly 100% or more on its first day of trading and the only IPO since 2000...
DRNA: 9.49 (+0.21), RARE: 42.35 (+1.19), VRNS: 21.93 (-0.57), RWLK: 29.52 (-0.63), CSLT: 11.65 (+0.24)
Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia
GlobeNewswire - Mon Sep 15, 9:04AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a long-term Phase 1/2 extension study, conducted by Kyowa Hakko Kirin Pharma, Inc., of the investigational fully human anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). The cumulative 16-month data, combining the four-month dose escalation period data from INT-001 and the 12-month extension data from INT-002, were presented at the American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Houston.
RARE: 42.35 (+1.19)
Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 12:55pm ET at the Grand Hyatt in New York.
RARE: 42.35 (+1.19), MS: 35.75 (-0.13)
Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Wed Sep 03, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive interim data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Innsbruck, Austria.
RARE: 42.35 (+1.19)
Ultragenyx to Present at the Baird Health Care Conference
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Tom Kassberg, the company's Chief Business Officer, will be presenting at the Robert W. Baird & Co. 2014 Health Care Conference on September 3, 2014 at 1:45pm ET in New York.
RARE: 42.35 (+1.19)
3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Tue Aug 26, 6:00AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
TNXP: 7.34 (-0.07), RARE: 42.35 (+1.19), RLYP: 18.92 (-0.98)
Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:41AM CDT
Ultragenyx (RARE) Shares March Higher, Can It Continue?
RARE: 42.35 (+1.19)
Company News for August 12, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 9:10AM CDT
Companies in the News are: DF,SYY,VHI,RARE
RARE: 42.35 (+1.19), VHI: 5.80 (unch), SYY: 38.33 (-0.32), DF: 16.24 (-0.16)
Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 11, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the second quarter ended June 30, 2014.
RARE: 42.35 (+1.19)
Recent News posted below.
RARE Ultragenyx Pharmaceutical Inc. Recent Headline News
Ultragenyx Pharmaceutical misses by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:12AM CST
RARE: 42.35 (+1.19)
Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Nov 10, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the third quarter ended September 30, 2014.
RARE: 42.35 (+1.19)
Ultragenyx to Present at the Credit Suisse Annual Healthcare Conference
GlobeNewswire - Tue Nov 04, 8:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Credit Suisse Annual Healthcare Conference on November 11, 2014 at 7:30am MT at the Biltmore Hotel in Phoenix.
RARE: 42.35 (+1.19)
Ultragenyx Granted EU Orphan Drug Designation for KRN23 for the Treatment of X-Linked Hypophosphatemia
GlobeNewswire - Thu Oct 30, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the European Commission has granted orphan medicinal product designation for recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23 (KRN23 or UX023) for the treatment of X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
RARE: 42.35 (+1.19)
Ultragenyx's Glut1 DS product candidate tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:51AM CDT
RARE: 42.35 (+1.19)
Ultragenyx Granted Orphan Drug Designation for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome
GlobeNewswire - Mon Oct 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS). Glut1 DS, also known as De Vivo disease, is a rare and potentially severely debilitating disease characterized by seizures, developmental delay, and movement disorder. Ultragenyx is conducting a Phase 2 study of triheptanoin in patients with Glut1 DS.
RARE: 42.35 (+1.19)
Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.01 (-0.31), EBS: 24.51 (+0.56), RARE: 42.35 (+1.19), LGND: 56.95 (+1.27)
Ultragenyx Pharmaceutical is Now Oversold (RARE)
MarketNewsVideo.com - Tue Oct 14, 3:34PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
RARE: 42.35 (+1.19)
Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
GlobeNewswire - Mon Oct 13, 8:45AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a Phase 2 extension study of sialic acid extended-release (SA-ER, UX001) tablets in patients with hereditary inclusion body myopathy (HIBM; also known as GNE myopathy), a rare, progressive muscle-wasting disease. SA-ER is designed to replace the deficient sialic acid substrate in patients with HIBM. The data were presented at the 19 International Congress of the World Muscle Society (WMS) in Berlin.
RARE: 42.35 (+1.19)
Ultragenyx to Present at the Leerink Partners Rare Disease Roundtable
GlobeNewswire - Wed Sep 24, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Leerink Partners Rare Disease Roundtable on October 1, 2014 at 9:40am ET at the Le Parker Meridien Hotel in New York.
RARE: 42.35 (+1.19)
Move Over Alibaba, These Are The Top 5 IPOs Of 2014
at Investor's Business Daily - Tue Sep 23, 7:02AM CDT
The Alibaba Group (BABA) mania may be cooling down but the IPO market continues to roar. The 2014 market for initial public offerings has been the busiest period since the 1999-2000 era of the dot-com bubble mania. There have been 195 IPOs on U.S....
GPRO: 74.45 (-1.30), RARE: 42.35 (+1.19), RWLK: 29.52 (-0.63), LOCO: 35.28 (-1.31), ZEN: 23.16 (-1.07), BABA: 114.72 (-4.43)
IPO Stock Watch: ReWalk Joins An Exclusive IPO Club
at Investor's Business Daily - Mon Sep 15, 5:56PM CDT
ReWalk Robotics (RWLK) stock rose 45% Monday on the heels of its eye-popping IPO Friday that joined an exclusive group. ReWalk was the fifth initial public offering this year to fly 100% or more on its first day of trading and the only IPO since 2000...
DRNA: 9.49 (+0.21), RARE: 42.35 (+1.19), VRNS: 21.93 (-0.57), RWLK: 29.52 (-0.63), CSLT: 11.65 (+0.24)
Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia
GlobeNewswire - Mon Sep 15, 9:04AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a long-term Phase 1/2 extension study, conducted by Kyowa Hakko Kirin Pharma, Inc., of the investigational fully human anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). The cumulative 16-month data, combining the four-month dose escalation period data from INT-001 and the 12-month extension data from INT-002, were presented at the American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Houston.
RARE: 42.35 (+1.19)
Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 12:55pm ET at the Grand Hyatt in New York.
RARE: 42.35 (+1.19), MS: 35.75 (-0.13)
Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Wed Sep 03, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive interim data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Innsbruck, Austria.
RARE: 42.35 (+1.19)
Ultragenyx to Present at the Baird Health Care Conference
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Tom Kassberg, the company's Chief Business Officer, will be presenting at the Robert W. Baird & Co. 2014 Health Care Conference on September 3, 2014 at 1:45pm ET in New York.
RARE: 42.35 (+1.19)
3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Tue Aug 26, 6:00AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
TNXP: 7.34 (-0.07), RARE: 42.35 (+1.19), RLYP: 18.92 (-0.98)
Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:41AM CDT
Ultragenyx (RARE) Shares March Higher, Can It Continue?
RARE: 42.35 (+1.19)
Company News for August 12, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 9:10AM CDT
Companies in the News are: DF,SYY,VHI,RARE
RARE: 42.35 (+1.19), VHI: 5.80 (unch), SYY: 38.33 (-0.32), DF: 16.24 (-0.16)
Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 11, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the second quarter ended June 30, 2014.
RARE: 42.35 (+1.19)
